They demonstrated that the overexpression of lncRNA MEG3 may inhibit the expression of TGF-β1 and VEGF to ameliorate diabetic retinopathy, which suggests the up-regulation of the lncR MEG3 as a promising therapy for diabetic vascular complications (84). The gene discussed is MEG3; the disease is complication.